Efficacy of a topical combination drug containing calcipotriol hydrate and betamethasone dipropionate for psoriasis

DOI Web Site Web Site 2 References Open Access

Bibliographic Information

Other Title
  • 乾癬治療におけるカルシポトリオール水和物＋ ベタメタゾンジプロピオン酸エステル配合外用薬の効果の検討
  • カンセンチリョウ ニ オケル カルシポトリオール スイワブツ+ベタメタゾンジプロピオンサン エステル ハイゴウ ガイヨウヤク ノ コウカ ノ ケントウ

Search this article

Description

Objective : Dovobet® ointment, a topical medication combining calcipotriol hydrate and betamethasone dipropionate (i.e., both activated vitamin D3 and a corticosteroid) became available in Japan in September 2014. We investigated the usefulness of Dovobet® ointment during routine treatment of Japanese outpatients attending our dermatology department from March to September 2015. Results : There were a total of 111 psoriasis patients, and Dovobet® ointment was prescribed to 67 patients (60.4%). Among these patients, the continuation rate of treatment with Dovobet® ointment was 78.0% (46/59 patients), after excluding 3 patients who failed to attend scheduled visits and 5 patients who discontinued this study owing to clinical trial participation. Analysis of the 15 patients who were switched from prior topical therapy with clobetasol propionate (Clobetasol), one of the strongest steroids, to Dovobet® ointment showed that complete switching to Dovobet® ointment was possible in 11/15 patients (73.3%). Conclusion : Treatment with Dovobet® ointment could be favorably continued in 68.7% of the patients, and 72.3% of these patients were stable on Dovobet® monotherapy. This topical medication was shown to be a readily acceptable treatment for psoriasis. Treatment of psoriasis with Dovobet® ointment was considered to be more desirable in terms of efficacy, safety, and cost compared with the use of corticosteroids from the strongest class.

Journal

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top